Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 13/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30448458 | 1.00 | CYP1A2 (0.46) | CYP1A2ACACBEPAS1HSD11B1FPR2 | |
| SCHEMBL31087500 | 0.83 | ACACB (0.38) | ACACBFPR2PROKR1 | |
| SCHEMBL26602975 | 0.83 | ACACB (0.38) | ACACBFPR2PROKR1 | |
| SCHEMBL16858563 | 0.83 | CYP1A2 (0.36) | CYP1A2ACACBEPAS1 | |
| SCHEMBL22711938 | 0.79 | CYP1A2 (0.31) | CYP1A2 | |
| SCHEMBL30856679 | 0.74 | KMT2A (0.41) | EPAS1 | |
| SCHEMBL22711889 | 0.74 | MBOAT4 (0.33) | ACACB | |
| SCHEMBL29195489 | 0.74 | KMT2A (0.41) | EPAS1 | |
| SCHEMBL20190609 | 0.73 | CYP1A2 (0.41) | CYP1A2ACACB | |
| SCHEMBL22711853 | 0.72 | DGAT1 (0.43) | ACACBEPAS1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376475-A1 | ION CHANNEL MODULATORS | PRAXIS PREC MEDICINES INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4487916-A2 | ION CHANNEL MODULATORS | Praxis Precision Medicines, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| EP-4397308-A2 | COMPOUNDS AND THEIR METHODS OFUSE | Praxis Precision Medicines, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20240132501-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-04-25 | — | — | US | disclosed |
| EP-3548033-B1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117756800-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-11918571-B2 | Compounds and their methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-11866439-B2 | Ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20210163488-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-06-03 | — | — | US | disclosed |
| US-11014931-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator | PRAXIS PRECISION MEDICINES, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3801535-A1 | ION CHANNEL MODULATORS | Praxis Precision Medicines, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20210087197-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-03-25 | — | — | US | disclosed |
| CN-112423760-A | Ion channel modulators | 普拉克西斯精密药物股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20200179358-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2020-06-11 | — | — | US | disclosed |
| EP-3548033-A1 | COMPOUNDS AND THEIR METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2019035951-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918571-B2 | Compounds and their methods of use | SCN1A, SCN3A, SCN2A | CYP1A2 2676/4885ACACB 901/4885EPAS1 2793/4885 |
| US-20240132501-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | CYP1A2 2873/4885ACACB 2004/4885EPAS1 2556/4885 |
| US-20210087197-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | CYP1A2 2873/4885ACACB 2004/4885EPAS1 2556/4885 |
| US-11866439-B2 | Ion channel modulators | SCN1A, SCN3A, SCN2A | CYP1A2 2873/4885ACACB 2004/4885EPAS1 2556/4885 |
| US-20210163488-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | CYP1A2 2873/4885ACACB 2004/4885EPAS1 2556/4885 |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885ACACB 814/4885EPAS1 2711/4885 |
| US-11014931-B2 | 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine as an ion channel modulator | SCN3A, SCN1A, SCN5A | CYP1A2 2631/4885ACACB 3534/4885EPAS1 1867/4885 |
| US-20250376475-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | CYP1A2 2873/4885ACACB 2004/4885EPAS1 2556/4885 |
| US-20200179358-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN2A | CYP1A2 2676/4885ACACB 901/4885EPAS1 2793/4885 |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885ACACB 814/4885EPAS1 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.